<DOC>
	<DOCNO>NCT00740493</DOCNO>
	<brief_summary>In French multicenter double blind randomize controlled trial , main objective demonstrate , 6 month oral anticoagulation first episode idiopathic proximal deep vein thrombosis , 18 month warfarin therapy associate lower cumulative risk recurrent VTE major bleed comparison 18 month placebo . The secondary objective : ( 1 ) determine risk recurrent VTE 6 month warfarin therapy presence absence residual lung scan perfusion defect persistence elevate D-dimer test ; ( 2 ) , determine impact extend duration anticoagulation risk VTE stop anticoagulant therapy follow-up 2 year .</brief_summary>
	<brief_title>Prolonged Anticoagulation After First Episod Idiopathic Proximal Deep Vein Thrombosis ( PADIS TVP )</brief_title>
	<detailed_description>Rational : After 3 6 month oral anticoagulation episode acute venous thromboembolism ( VTE ) , risk recurrent VTE high ( 10 15 % per year ) comparison low risk recurrence VTE provoke major transient risk factor recent surgery ( 3 % per year ) independently initial presentation ( deep vein thrombosis pulmonary embolism ) . After first episode idiopathic VTE , 3 month anticoagulation associate high risk recurrence ( 27 % per year ) ; however , benefit-risk extended duration anticoagulation ( 1 2 year ) remain uncertain , mainly relation increase risk anticoagulant relate bleeding . Therefore , last ACCP conference group recommend 6 month oral anticoagulant therapy first episode idiopathic VTE . However , recommendation likely inadequate least two main reason : ( 1 ) study compare 2 year 6 month anticoagulation idiopathic VTE ; ( 2 ) , frequency recurrent VTE similar deep vein thrombosis pulmonary embolism , however , case fatality rate recurrent VTE high pulmonary embolism ( 12 % ) deep vein thrombosis ( 5 % ) . Objective : main objective demonstrate , 6 month oral anticoagulation first episode idiopathic proximal deep vein thrombosis , 18 month warfarin therapy associate lower cumulative risk recurrent VTE major bleed comparison 18 month placebo . The secondary objective : ( 1 ) determine risk recurrent VTE 6 month warfarin therapy presence absence residual lung scan perfusion defect persistence elevate D-dimer test ; ( 2 ) , determine impact extend duration anticoagulation risk VTE stop anticoagulant therapy follow-up 2 year . Method : French multicenter double blind randomize control trial . Inclusion exclusion criterion deep vein thrombosis diagnostic criterion define . After complete 6 month oral anticoagulation , leg ultrasound D-dimer test perform ; investigator patient unaware result test . Then , patient randomize receive 18 month warfarin therapy 18 month placebo ( dose placebo adapt accord false computer generate INR ) . The investigator , radiologists patient blind treatment allocation . The project accept national ethical committee write consent obtain include patient . Required number patient : expect cumulative frequency recurrent VTE major bleed 18 month 4.5 % warfarin therapy 16 % placebo . For α risk 5 % ( falsely conclude true difference ) β risk 10 % ( falsely conclude absence difference ) , 178 patient per group include . As 5 % patient expect loss , total 374 patient require . Feasibility : 50 patient per year hospitalize department medicine Brest acute episode idiopathic deep vein thrombosis . Four additional center participate study similar recruitment : HEGP ( Pr Meyer , Dr Sanchez ) , CHU Antoine Béclère ( Dr Parent , Pr Simmoneau ) , CHU Saint Etienne ( Pr Mismetti , Pr Décousus ) , CHU Grenoble ( Pr Pison , Pr Carpentier ) . The study coordinate Clinical Center Investigation Brest Hospital ; `` true '' `` false '' INR generate clinic anticoagulant `` Ile de France '' ( Dr Cambus ) . Clinical implication : first consequence study demonstrate 6 month warfarin therapy inadequate continue least 18 additional month first episode idiopathic proximal deep vein thrombosis . This study also potential confirm contribution ultrasound low limb D-dimer test appreciate risk recurrent VTE stop anticoagulant therapy . Lastly , medical economical impact therapeutic management evaluate .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients first episode idiopathic proximal deep vein thrombosis treat 6 month ( Plus minus 15 day ) use Vitamin K antagonist INR 2 3 . Age &gt; 18 warfarin hypersensibility unwilling unable give writting inform consent distal deep vein thrombosis pulmonary embolism Proximal deep vein thrombosis provoke reversible major risk factor major thrombophilia ( protein C , S antithrombin deficiency , antiphospholipids antibody , homozygous factor V Leiden ) previous document episode proximale deep vein thrombosis pulmonary embolism indication anticoagulant therapy ( e.g . : atrial fibrillation , mechanic valve ) patient antithrombotic agent antithrombotic agent start stop anticoagulation pregnancy woman without contraception plan major surgery next 18 month ongoing cancer cure cancer le 2 year serious bleed risk ( e.g . : gastric ulcer ) platelet count le 100 Giga/l Life expectancy le 18 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent venous thromboembolism</keyword>
	<keyword>idiopathic deep vein thrombosis</keyword>
	<keyword>optimal duration anticoagulation</keyword>
</DOC>